Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 6 (5) |
| Completed vs Stopped Early | 7 / 4 (23.5%) |
| Median Closed Actual Enrollment | 64 participants |
| Physical Hospital Site Disclosure | 99.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Duke University Medical Center | Durham, NC | 3 |
| Toronto General Hospital | Toronto, Ontario | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07220915 | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Phase III | RECRUITING |
| NCT04918173 | Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery | Phase III | RECRUITING |
| NCT06096116 | Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo | Phase III | RECRUITING |
| NCT04867837 | Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Octapharma Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.